Quest Diagnostics CFO Sam Samad Acquires 90 Shares via Dividend Reinvestment

Executive Summary

On October 23, 2026, Quest Diagnostics Inc ($DGX) filed a Form 4 disclosing that Executive Vice President and Chief Financial Officer Sam Samad acquired 90 shares of common stock on October 21, 2026. The shares were acquired at an average price of $235.939 per share, totaling approximately $21,234.51.

Transaction Analysis

• Nature of Acquisition: Per the footnote disclosure, these shares were acquired automatically pursuant to a dividend reinvestment plan (DRIP) administered by the reporting person's broker. Although eligible for deferred reporting on Form 5 under Rule 16a-6, the reporting person elected to report early on Form 4.
• Holdings Impact: Following the acquisition, Mr. Samad directly holds 33,568 shares of Quest Diagnostics common stock. The 90-share purchase represents a fractional increase (<0.3%) in total direct holdings.
• Significance: Because this acquisition is the result of an automated dividend reinvestment rather than a discretionary open-market buy order, it provides minimal directional predictive value regarding executive sentiment or business prospects.